Pursuing new paths in targeted protein degradation drug development

Ian Churcher of Amphista highlights opportunities and how the next generation of targeted protein degradation (TPD) therapy are developing to overcome existing limitations.

Related Keywords

Ian Churcher , ,Chief Science Officer ,